1. Introduction
Pancreatic cancer is the third leading cause of cancer-related deaths in the United States, responsible for over 48,000 deaths each year [
1]. In fact, it is projected to become the second most common cause of cancer-related deaths by the year 2040 [
2]. Treatment of localized disease usually involves a combination of chemotherapy, radiation therapy, and surgical resection [
3]. Unfortunately, even with aggressive therapy, outcomes are guarded with a five-year overall survival (OS) rate of less than 15% for borderline resectable and locally advanced pancreatic cancer (BRPC/LAPC) [
4].
Pancreatic cancer can be considered a disease of older patients with the median age of diagnosis of 70 years [
5]. In fact, two thirds of newly diagnosed patients are over 65 years [
5]. As our population continues to age, the incidence of pancreatic cancer in the older patients is expected to increase [
6]. However, optimal management of this group of patients is largely unknown given that clinical trials consist predominantly of younger patients, and as such, the results cannot necessarily be applied to the treatment of older patients [
7,
8]. Furthermore, only a small proportion of older patients currently receive what would be considered standard of care therapy for non-older patients [
9,
10,
11,
12]. In fact, one study demonstrated that only 44% of patients over 65 years with LAPC received any treatment at all [
13]. As such, more information is needed regarding the optimal management of older patients with pancreatic cancer.
Older patients are more likely to have co-morbidities or poor performance status that precludes aggressive therapy such as surgical resection and adjuvant therapy [
9]. Stereotactic body radiation therapy (SBRT), which is used for the purpose of margin sterilization in the neoadjuvant setting or for improved local progression-free survival (LPFS) in the definitive/unresectable setting, may have a role in these patients. There have been only a handful of studies investigating the role of SBRT in older patients [
14,
15,
16,
17,
18]. Unfortunately, many of these studies are limited by heterogeneous treatment and disease characteristics. As such, we report on a cohort of older patients (age ≥ 70 years) with BRPC/LAPC who were treated with upfront chemotherapy followed by five-fraction SBRT with or without surgery. We report on clinical outcomes such as OS, LPFS, distant metastasis-free survival (DMFS), and progression-free survival (PFS), as well as on toxicity. We also compare practice patterns between older patients and patients < 70 years.
2. Materials and Methods
2.1. Study Design
This was a single institution retrospective review of patients with BRPC/LAPC who were treated with upfront chemotherapy followed by SBRT with or without surgery, with a focus on older patients (≥70 years), which comprised the study population. The study was approved by our institutional review board. The inclusion criteria were as follows: (1) Biopsy proven diagnosis of pancreatic cancer; (2) Age ≥ 70 years; (3) BRPC or LAPC per NCCN criteria [
3]; (4) Treatment with upfront chemotherapy followed by SBRT; (5) Regular follow-up with diagnostic imaging available for review. Clinical outcomes and toxicity were evaluated for older patients. In addition, practice patterns of older patients were compared to that of the rest of the source population (<70 years). Radiation and chemotherapy-related toxicity were evaluated with the Common Terminology Criteria for Adverse Events (CTCAE) criteria, and postoperative toxicity was assessed within 90 days after surgery with Clavien–Dindo classification.
2.2. Definition of Clinical Outcomes
Clinical outcomes included OS, LPFS, DMFS, and PFS. Overall survival was defined as time from completion of SBRT to death. Patients who were alive were censored at time of last clinic visit. Local-progression free survival and DMFS were defined as time from completion of SBRT to development of locoregional disease and distant disease on imaging, respectively. Death was not included as an endpoint when evaluating LPFS and DMFS. Patients who did not experience local progression or distant disease were censored at time of last imaging follow-up. Progression-free survival was defined as time from completion of SBRT to development of any radiographic evidence of disease progression or death. Patients who did not experience any progression were censored at time of last imaging follow-up.
2.3. General Treatment Paradigm
At our institution, all patients with BRPC/LAPC were treated with upfront chemotherapy, with a preference for multi-agent regimens when feasible. During chemotherapy, pancreatic protocol computed tomography (CT) scans were performed at approximately three-month intervals to assess treatment response. After completion of chemotherapy, patients were recommended for five-fraction SBRT if they had stable or responding disease. After completion of SBRT, patients had re-staging diagnostic imaging. All BRPC patients were taken for surgical exploration if they had imaging evidence of disease response/stability and no medical contraindications. The same was true for LAPC, with the exception of patients with extensive local disease characterized by encasement of multiple arterial structures or occlusion of venous structures with collateral formation, precluding a reasonable pathway for surgical resection.
2.4. SBRT Treatment Details
After completion of upfront chemotherapy, patients were planned for five-fraction SBRT. Prior to simulation, all patients had endoscopic ultrasound-guided placement of gold fiducials to assist with image guidance. At time of simulation, patients were placed supine with arms above head and immobilized in a Vac-Lok (CIVCO Medical Solutions, Coralville, IA, USA). Thin-sliced CT scans with intravenous contrast were acquired for treatment planning. Target volumes and organs at risk were delineated using Pinnacle Treatment Planning System (Phillips Radiation Oncology Systems, Fitchburg, WI, USA). Active breathing control (ABC, Elekta, Stockholm, Sweden) was utilized for motion management. Patients who could not tolerate breath hold underwent a four-dimensional CT scan, and an internal target volume (ITV) was generated from the maximum inspiratory and expiratory phases. The clinical target volume (CTV) consisted of gross disease on imaging in addition to full circumference of involved vasculature. The planning target volume (PTV) was generated by adding 3–5 mm isotropic expansion to the CTV in breath-hold cases and to the ITV in free breathing cases. Daily image guidance with pre-treatment and intrafraction cone beam CT scans was performed to ensure appropriate patient positioning. Patients were aligned to bone and then shifted to align to fiducials. All patients were treated on an Elekta linear accelerator unit (Elekta, Stockholm, Sweden).
2.5. Statistical Analysis
Patient, treatment, and disease characteristics were recorded including age, sex, Eastern Cooperative Oncology Group score, Adult Comorbidity Evaluation-27 score, tumor location, disease extent, baseline cancer antigen 19-9 (CA 19-9) and total bilirubin, chemotherapy type and duration, SBRT dose and fractionation, PTV size, and resection status. Univariate Cox analysis (UVA) was performed to evaluate associations between the aforementioned variables with clinical outcomes. Variables with p < 0.05 on UVA were entered into multivariable Cox analysis (MVA). Kaplan-Meier analysis was performed for survival outcomes, and log-rank test was used to assess significance between groups. Chi-square and Mann–Whitney U tests were used to assess differences in practice patterns and toxicity between various groups. A p value < 0.05 was considered significant and all p values were two-sided. Statistical analysis was performed with JMP version 15.0 (SAS institute, Cary, NC, USA)
4. Discussion
In this study, we demonstrate that in older patients who complete chemotherapy, aggressive local treatment with SBRT and surgery is well tolerated, with just three events (5.3%) of late grade 3 radiation toxicity and two events (5.3%) of Clavien-Dindo grade 3b toxicity in those who underwent resection. We also show that surgical resection is associated with improved clinical outcomes such as OS, DMFS and PFS, including an impressive median OS of 29.1 months.
Older patients with pancreatic cancer represent a challenging population given the aggressive nature of the disease and because many will not be candidates for multimodality therapy due to co-morbidities and poor performance status. As such, older patients (≥70 years) are underrepresented in clinical trials, accounting for 46% of the United States cancer population, but compromising only 20% of trial participants [
7,
8]. As such, the optimal management for these patients is unknown. Furthermore, many older patients do not receive standard of care treatment. Studies have shown that older patients are less likely to undergo surgical resection and receive adjuvant chemotherapy [
19,
20,
21]. In addition, a study by Krzyzanwoska et al. of LAPC, demonstrated that only 44% of older patients received any form of treatment [
13]. Therefore, additional studies are warranted to determine the most appropriate management for this group of patients.
Several studies have demonstrated the feasibility of SBRT in older patients and are shown in
Table 6 [
14,
15,
16,
17,
18]. Three studies, including the current study, included older patients who underwent surgery. While cross-study comparisons are limited and our cohort was likely more fit given that all patients completed chemotherapy, the fact that a large proportion (67%) underwent surgical resection is noteworthy and higher than other studies (34%, 10%) [
16,
18]. This likely led to the higher median OS in our patients (19.6 versus 14.0 and 10–13 months) [
16,
18]. Conversely, the median OS was < 10 months in the studies, which included only inoperable patients [
14,
15,
17]. In the current report, patients who underwent resection had improved median OS (29.1 vs. 7.0 months,
p = 0.005). Sutera et al. demonstrated similar results (28.3 vs. 11.4 months,
p = 0.002) [
18]. Interestingly, the disease extent was similar in our study (BRPC: 47.4%, LAPC: 52.6%) to that of Sutera et al. (resectable/BRPC: 46.2%, LAPC: 53.8%) and Zhu et al. (BRPC: 32.5%, LAPC: 67.5%). The difference in resection rate can likely be attributed to institution-specific surgical practice patterns. For example, at our institution, all BRPC/LAPC are taken for surgical exploration as long as they have stable disease, no medical contraindications, and if there is a reasonable pathway for resection. Additionally, our cohort was likely more fit given that we selected for patients who completed chemotherapy. Of the 19 patients who did not undergo resection in our cohort, only two had medical contraindications/advanced age. Of the 38 patients who underwent resection, 22 (57.9%) and 2 (5.3%) experienced Clavien-Dindo grades < 3a and 3b toxicity, respectively, which is consistent with rates from other series, which included patients of all ages [
22,
23]. These findings suggest that surgery can be well tolerated in older in patients who complete chemotherapy and should not be withheld solely based on age criteria, as resection may significantly improve outcomes in these patients.
Unfortunately, some older patients are unfit for surgical resection or aggressive systemic therapy. These patients may be at risk of uncontrolled tumor growth, which can cause significant local morbidity such as cholangitis, biliary obstruction, GI bleeding, and celiac plexopathy, which in turn, can drive both morbidity and mortality [
24]. In fact, the median OS for untreated pancreatic cancer is just 2.5 months [
25]. Therefore, minimally invasive treatments, such as SBRT, are important for this group of patients. Several studies have investigated the role of SBRT in inoperable older patients, with encouraging results [
14,
15,
17]. Kim et al. reported on 26 patients with a median age of 86 years, who were treated with SBRT + chemotherapy [
14]. They reported a median OS of 7.6 months and 1-year LPFS rate of 41.2%, with no late grade > 3 toxicity. Of note, there was a 70% rate of symptom relief after SBRT. Ryan et al. reported on 29 patients with inoperable disease treated with SBRT + chemotherapy [
17]. They reported a median OS of 8.0 months and 1-year LPFS of 78%, with a symptom relief rate of 58%. There was only one episode of late grade 3 toxicity. In the current study, 19 patients underwent SBRT alone, with a median OS of 7.0 months and one-year LPFS of 72.0%. There were no late grade > 3 radiation toxicity events. Interestingly, the one-year LPFS rate reported by Kim et al. is significantly lower, despite utilizing a higher median biologically effective dose. One explanation is that a lower percentage (48%) of patients received chemotherapy when compared to the study by Ryan et al. (83%) and our study (100%), highlighting the role of systemic therapy in local control. Taken together, these findings demonstrate that SBRT for older patients with medically inoperable/unresectable disease is safe, feasible, and can provide adequate symptom relief.
One area of active investigation, which may be relevant to older patients, is dose escalation for inoperable pancreatic cancer. Retrospective data has shown that increased radiation dose can improve both OS and LPFS [
26,
27,
28,
29]. Studies, including the current one, demonstrate that SBRT to conventional doses is safe and feasible, but that outcomes can be suboptimal especially in older patients who cannot undergo surgical resection or receive systemic therapy [
14,
15,
16,
17,
18]. Therefore, dose-escalated therapy may be of benefit in these patients. However, very little is known about the safety of increased radiation dose in older patients. Additionally, the prolonged treatment time associated with dose escalation must weighed against the limited life expectancy and potential detriment to quality of life in these patients. As such, further studies investigating the safety and efficacy of dose escalation in this older population is warranted.
There are some limitations of the current study, including its retrospective design. Patients received various chemotherapy regimens, which may have impacted clinical outcomes, although this was controlled for during statistical analysis. Our study population was also likely more fit when compared to others, because we only included patients who completed chemotherapy, limiting cross-study comparisons. Moreover, it also would have been useful to demonstrate underutilization of local therapies in elderly patients as compared to other age groups, certainly a worthwhile subject of future study, but this was not possible with our institutional data. Furthermore, some patients had follow-up locally at outside institutions, likely leading to underreporting of treatment-related toxicity. We were also unable to comment on symptom palliation as this information was not available for review. The strengths of this study include its relatively large sample size, homogenous treatment characteristics with regards to general treatment paradigm and SBRT dose/fractionation, and long follow-up time. Despite the study’s limitations, the findings add relevant information to the role of SBRT in the treatment of older patients.